Long-term effects on vascular healing of bare metal stents delivered via paclitaxel-coated balloons in the porcine model of restenosis

Catheterization and Cardiovascular Interventions

Volumn 80, Issue 4, 2012, Pages 603-610

  Cremers, Bodo ^a   Milewski, Krzysztof ^b   Clever, Yvonne P ^a   Aboodi, Michael S ^b   Biedermann, Melanie ^c   Thim, Troels ^d   Kelsch, Bettina ^c   Kaluza, Greg L ^b   Scheller, Bruno ^a,e   Granada, Juan F ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^c HUMBOLDT UNIVERSITY   (Germany)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e SAARLAND UNIVERSITY   (Germany)

Author keywords

paclitaxel coated balloon; porcine; stent; vascular healing

Indexed keywords

PACLITAXEL; RAPAMYCIN; VON WILLEBRAND FACTOR;

ANGIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BALLOON; BALLOON CATHETER; BARE METAL STENT; CONTROLLED STUDY; CORONARY ARTERY; DRUG ELUTING STENT; FOLLOW UP; HISTOLOGY; IMPLANTATION; IN-STENT RESTENOSIS; INFLAMMATION; NONHUMAN; PACLITAXEL COATED BALLOON; PROTEIN EXPRESSION; REVIEW; SCORING SYSTEM; SWINE;

ANGIOPLASTY, BALLOON, CORONARY; ANIMALS; CARDIAC CATHETERS; CARDIOVASCULAR AGENTS; CELL PROLIFERATION; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY VESSELS; DISEASE MODELS, ANIMAL; DRUG-ELUTING STENTS; ENDOTHELIAL CELLS; EQUIPMENT DESIGN; METALS; NEOINTIMA; PACLITAXEL; PROSTHESIS DESIGN; STENTS; SWINE; SWINE, MINIATURE; TIME FACTORS; VON WILLEBRAND FACTOR;

EID: 84866737543     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.24305     Document Type: Review

References (33)

1. Gray WA, Granada JF,. Drug-coated balloons for the prevention of vascular restenosis. Circulation 2010; 121: 2672-2680.
2. Cremers B, Biedermann M, Mahnkopf D, Bohm M, Scheller B,. Comparison of two different paclitaxel-coated balloon catheters in the porcine coronary restenosis model. Clin Res Cardiol 2009; 98: 325-330.
3. Scheller B, Speck U, Abramjuk C, Bernhardt U, Bohm M, Nickenig G,. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation 2004; 110: 810-814.
4. Speck U, Scheller B, Abramjuk C, Breitwieser C, Dobberstein J, Boehm M, Hamm B,. Neointima inhibition: Comparison of effectiveness of nonstent-based local drug delivery and a drug-eluting stent in porcine coronary arteries. Radiology 2006; 240: 411-418.
5. Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Bohm M, Speck U,. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 2006; 355: 2113-2124.
6. Unverdorben M, Vallbracht C, Cremers B, Heuer H, Hengstenberg C, Maikowski C, Werner GS, Antoni D, Kleber FX, Bocksch W, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 2009; 119: 2986-2994.
7. Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwalder U, Beregi JP, Claussen CD, Oldenburg A, Scheller B, Speck U,. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 2008; 358: 689-699.
8. Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, Dietz U, Hosten N, Hamm B, Speck U, Ricke J,. Inhibition of restenosis in femoropopliteal arteries: Paclitaxel-coated versus uncoated balloon: Femoral paclitaxel randomized pilot trial. Circulation 2008; 118: 1358-1365.
9. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR,. Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine model. J Am Coll Cardiol 1992; 19: 267-274.
10. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB,. In-stent restenosis: Contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998; 31: 224-230.
11. Maier LS, Maack C, Ritter O, Bohm M,. Hotline update of clinical trials and registries presented at the German Cardiac Society meeting 2008. (PEPCAD, LokalTax, INH, German ablation registry, German device registry, DES.DE registry, DHR, Reality, SWEETHEART registry, ADMA, GERSHWIN). Clin Res Cardiol 2008; 97: 356-363.
12. Poss J, Jacobshagen C, Ukena C, Bohm M,. Hotlines and clinical trial updates presented at the German Cardiac Society Meeting 2010: FAIR-HF, CIPAMI, LIPSIA-NSTEMI, Handheld-BNP, PEPCAD III, remote ischaemic conditioning, CERTIFY, PreSCD-II, German Myocardial Infarction Registry, DiaRegis. Clin Res Cardiol 2010; 99: 411-417.
13. Carter AJ, Aggarwal M, Kopia GA, Tio F, Tsao PS, Kolata R, Yeung AC, Llanos G, Dooley J, Falotico R,. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res 2004; 63: 617-624.
14. Farb A, Heller PF, Shroff S, Cheng L, Kolodgie FD, Carter AJ, Scott DS, Froehlich J, Virmani R,. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 2001; 104: 473-479.
15. Scheller B, Grandt A, Wnendt S, Lorenz G, Bohm M, Nickenig G,. Comparative study of tacrolimus and paclitaxel stent coating in the porcine coronary model. Z Kardiol 2005; 94: 445-452.
16. Wilson GJ, Polovick JE, Huibregtse BA, Poff BC,. Overlapping paclitaxel-eluting stents: Long-term effects in a porcine coronary artery model. Cardiovasc Res 2007; 76: 361-372.
17. Park DW, Hong MK, Mintz GS, Lee CW, Song JM, Han KH, Kang DH, Cheong SS, Song JK, Kim JJ, et al. Two-year follow-up of the quantitative angiographic and volumetric intravascular ultrasound analysis after nonpolymeric paclitaxel-eluting stent implantation: Late "catch-up" phenomenon from ASPECT Study. J Am Coll Cardiol 2006; 48: 2432-2439.
18. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356: 998-1008.
19. Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Bohm M, Speck U,. Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol 2008; 97: 773-781.
20. Fajadet J, Morice MC, Bode C, Barragan P, Serruys PW, Wijns W, Constantini CR, Guermonprez JL, Eltchaninoff H, Blanchard D, et al. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: Three-year results of the RAVEL trial. Circulation 2005; 111: 1040-1044.
21. Daemen J, Ong AT, Stefanini GG, Tsuchida K, Spindler H, Sianos G, de Jaegere PP, van Domburg RT, Serruys PW,. Three-year clinical follow-up of the unrestricted use of sirolimus-eluting stents as part of the rapamycin-eluting stent evaluated at rotterdam cardiology hospital (RESEARCH) registry. Am J Cardiol 2006; 98: 895-901.
22. Caixeta A, Leon MB, Lansky AJ, Nikolsky E, Aoki J, Moses JW, Schofer J, Morice MC, Schampaert E, Kirtane AJ, et al. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents. J Am Coll Cardiol 2009; 54: 894-902.
23. Aoki J, Abizaid AC, Serruys PW, Ong AT, Boersma E, Sousa JE, Bruining N,. Evaluation of four-year coronary artery response after sirolimus-eluting stent implantation using serial quantitative intravascular ultrasound and computer-assisted grayscale value analysis for plaque composition in event-free patients. J Am Coll Cardiol 2005; 46: 1670-1676.
24. Raber L, Wohlwend L, Wigger M, Togni M, Wandel S, Wenaweser P, Cook S, Moschovitis A, Vogel R, Kalesan B, et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: Results of the sirolimus-eluting versus paclitaxel-eluting stents for coronary revascularization LATE trial. Circulation 2011; 123: 2819-2828; 6 p following 2828.
25. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Juni P, Sianos G, Hellige G, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 2007; 369: 667-678.
26. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K, Skorija K, Weber DK, Gold HK, Virmani R,. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005; 112: 270-278.
27. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293: 2126-2130.
28. Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J, Davidson CJ, McKoy JM, Raisch DW, Whisenant BK, et al. Hypersensitivity cases associated with drug-eluting coronary stents: A review of available cases from the research on adverse drug events and reports (RADAR) project. J Am Coll Cardiol 2006; 47: 175-181.
29. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C,. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006; 48: 2584-2591.
30. Schwartz RS, Edelman ER, Carter A, Chronos NA, Rogers C, Robinson KA, Waksman R, Machan L, Weinberger J, Wilensky RL, et al. Preclinical evaluation of drug-eluting stents for peripheral applications: Recommendations from an expert consensus group. Circulation 2004; 110: 2498-2505.
31. van Beusekom HM, Schwartz RS, van der Giessen WJ,. Synthetic polymers. Semin Interv Cardiol 1998; 3: 145-148.
32. van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HM, Serruys PW, Holmes DR Jr, Ellis SG, Topol EJ,. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996; 94: 1690-1697.
33. Schwartz RS, Edelman E, Virmani R, Carter A, Granada JF, Kaluza GL, Chronos NA, Robinson KA, Waksman R, Weinberger J, et al. Drug-eluting stents in preclinical studies: Updated consensus recommendations for preclinical evaluation. Circ Cardiovasc Interv 2008; 1: 143-153.